Moleculin Biotech is trading 8.35% up at $0.65 after opening-market strength on August 27, 2026, amid broader risk appetite following Nvidia’s strong results and outlook.
- No company-specific announcement dated August 27 was identified.
- The latest major update was the August 14 quarterly report covering MIRACLE trial progress.
- Nasdaq futures rose about 1% after Nvidia’s results and outlook, while broader U.S. indexes also advanced.